Jim Simons Trevena Inc Transaction History

Renaissance Technologies LLC

  • $56.7 Billion
  • Q2 2024

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$0.16 - $100.0 $16,304 - $10.2 Million
101,900 Added 10.25%
1,096,100 $168,000
Q2 2022

Aug 12, 2022
BUY
$0.2 - $0.5 $137,160 - $342,900
685,800 Added 222.37%
994,200 $412,000
Q1 2022

May 13, 2022
BUY
$0.41 - $0.63 $60,188 - $92,484
146,800 Added 90.84%
308,400 $170,000
Q4 2021

Feb 11, 2022
BUY
$0.57 - $1.29 $92,111 - $208,464
161,600 New
161,600 $94,000
Q2 2021

Aug 13, 2021
SELL
$1.46 - $2.25 $426,756 - $657,672
-292,299 Closed
0 $0
Q1 2021

May 13, 2021
SELL
$1.77 - $2.93 $1.41 Million - $2.34 Million
-798,901 Reduced 73.21%
292,299 $523,000
Q4 2020

Feb 10, 2021
BUY
$2.13 - $3.26 $1.84 Million - $2.81 Million
863,126 Added 378.44%
1,091,200 $2.34 Million
Q3 2020

Nov 13, 2020
SELL
$1.53 - $3.13 $5.25 Million - $10.7 Million
-3,433,300 Reduced 93.77%
228,074 $682,000
Q2 2020

Aug 13, 2020
BUY
$0.48 - $1.75 $546,432 - $1.99 Million
1,138,400 Added 45.12%
3,661,374 $5.49 Million
Q1 2020

May 14, 2020
BUY
$0.56 - $0.97 $111,126 - $192,487
198,441 Added 8.54%
2,522,974 $1.43 Million
Q4 2019

Feb 13, 2020
BUY
$0.62 - $1.06 $133,550 - $228,328
215,404 Added 10.21%
2,324,533 $1.96 Million
Q3 2019

Nov 13, 2019
BUY
$0.81 - $1.06 $146,025 - $191,095
180,279 Added 9.35%
2,109,129 $2.04 Million
Q2 2019

Aug 12, 2019
BUY
$0.94 - $1.6 $606,123 - $1.03 Million
644,812 Added 50.22%
1,928,850 $1.99 Million
Q1 2019

May 14, 2019
BUY
$0.51 - $1.88 $299,421 - $1.1 Million
587,100 Added 84.24%
1,284,038 $2 Million
Q4 2018

Feb 13, 2019
BUY
$0.39 - $3.47 $271,805 - $2.42 Million
696,938 New
696,938 $300,000

About TREVENA INC

TRVN Quotes by TradingView
  • Ticker TRVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 173,680,992
  • Market Cap $691M
  • Description
  • Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV...
More about TRVN
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email